Jz. Demoraes et al., ANTIIDIOTYPIC MONOCLONAL-ANTIBODY AB3, REACTING WITH THE PRIMARY ANTIGEN (CEA), CAN LOCALIZE IN HUMAN COLON-CARCINOMA XENOGRAFTS AS EFFICIENTLY AS AB1, International journal of cancer, 57(4), 1994, pp. 586-591
BALB/c mice were immunized with anti-idiotypic monoclonal (MAb) antibo
dy (anti-Id or Ab2) directed against an AB1 MAb anti-carcinoembryonic
(CEA) in order to obtain AB3 MAbs (anti-anti-Id). AB3 MAbs were shown
to recognise the primary antigen (CEA) and one of them was tested exte
nsively in vitro and in vivo. This AB3 MAb was shown to bind specifica
lly to CEA on frozen sections of a human colon carcinoma by immuoperox
idase. Scatchard plot analyses showed that the affinity of this AB3 wa
s of the same order of magnitude as the AB1. In vivo experiments, in n
ude mice bearing CEA-producing human colon-carcinoma xenografts showed
that up to 30% of the intravenously injected dose of I-125-labelled A
B3 were localized per gram of tumour tissue. Furthermore, calculation
of the ratios of AB3 concentration in the tumour over those in normal
organs such as lung, liver, kidney, spleen and bone gave relatively hi
gh values similar to results obtained with AB1. All together our resul
ts show that AB3 can localize as efficiently and specifically in the t
umour as AB1, despite the fact that the mice from which it was derived
were immunized with a mouse MAb (AB2) and had never been exposed to C
EA. (C) 1994 Wiley-Liss, Inc.